GoogleNews-Aggregator

UniQure has a new plan after last year's FDA imbroglio: head to the U.K. to seek approval of embattled Huntington's disease gene therapy AMT-130.Read more

Huntington's disease is a rare, inherited neurodegenerative disorder that progressively impairs movement, cognition, and behavior. AMT-130 ...Read more

... Application for AMT-130 for the treatment of Huntington's disease in the third quarter of 2026. “We are ...Read more

Shares of uniQure N.V. (QURE) jumped 8% on Thursday as investors cheered progress on its Huntington's disease therapy, with the company outlining ...Read more

30 April 2026. More on this story... Confusion grows amid uniQure and FDA's AMT-130 row · Biotechnology · Confusion grows amid uniQure and ...Read more

uniQure meets with UK MHRA on AMT-130 for Huntington's disease. 30 April 2026.Read more

... Huntington's disease in the third quarter of 2026. “We are encouraged ... disease, refractory temporal lobe epilepsy, Fabry disease, and other severe ...Read more

... Huntington's disease therapy Austedo (deutetrabenazine). Dipping its toe in the M&A water once again reflects that growing confidence, and shares ...Read more

... uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease. Provided By GlobeNewswire ...Read more

uniQure is moving AMT-130 for Huntington's disease toward a UK Marketing Authorization Application after a constructive pre-submission meeting with ...Read more

At the three-year mark, the data showed a 75% slowing of disease progression at the high dose as measured by the composite Unified Huntington's ...Read more

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease. Rhea-AI Impact.Read more

... Huntington's disease treatment in the third quarter of 2026. The gene therapy company discussed data package and manufacturing requirements with ...Read more

Huntington's disease (HD) is a progressive neurodegenerative disorder caused by an expanded cytosine–adenine–guanine (CAG) trinucleotide repeat in the ...Read more

... diseases, and autoimmune disorders ... Its lead candidate, Pepinemab, is being developed for Alzheimer's and Huntington's disease and is also under ...Read more